<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490555</url>
  </required_header>
  <id_info>
    <org_study_id>31434-A</org_study_id>
    <secondary_id>RFA-HD-06-014;</secondary_id>
    <secondary_id>06-4795-A 01</secondary_id>
    <nct_id>NCT00490555</nct_id>
  </id_info>
  <brief_title>PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue</brief_title>
  <acronym>PROS-1</acronym>
  <official_title>The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to examine the in vivo responses to hormonal manipulation at the
      molecular level directly in the tissue of interest (prostate). As in the investigators'
      previous, pilot study, the investigators will use the novel approach of procuring tissue
      specimens from normal, healthy men who might be chose to use a male hormonal contraceptive
      regimen were it available. The investigators will employ state of the art techniques such as
      laser capture microdissection (LCM) and cDNA microarrays to determine the tissue-specific
      consequences of male hormonal contraceptive regimens on the prostate. The results will help
      guide the design, safety monitoring, and selection of male hormonal contraceptive agents and
      provide valuable insights into prostate human prostate biology.

      The investigators will test the hypothesis that exogenous T administration that results in
      increased circulating T and dihydrotestosterone (DHT) levels will increase intraprostatic
      concentrations of T and its metabolite DHT.

      The investigators will test the hypothesis that the addition of a potent 5α-reductase
      inhibitor, dutasteride, or the progestin, Depomedoxyprogesterone (IM DMPA), to T
      administration in young and middle aged men will decrease intraprostatic DHT and increase
      intraprostatic T concentrations compared to T alone.

      The investigators will test the hypothesis that the addition of a 5α-reductase inhibitor
      dutasteride or the progestin IM DMPA to exogenous T, by reducing intraprostatic DHT, will
      decrease prostate epithelial proliferation, assessed by Ki-67 labeling index (Ki-67LI), and
      increase apoptosis, assessed by caspase-3 expression, and decrease androgen-regulated protein
      expression such as prostate specific antigen (PSA).

      The investigators will test the hypothesis that the addition of a 5α-reductase inhibitor or
      the progestin IM DMPA to exogenous T, by modifying the intraprostatic hormonal milieu, will
      alter prostate epithelial gene expression. Specifically, the investigators expect that the
      addition of the 5α-reductase inhibitor dutasteride or the progestin IM DMPA to exogenous T,
      will result in decreased expression of androgen-regulated genes such as PSA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to understand the effects of testosterone on the
      prostate. This knowledge will be used to help in the development of a safe male hormonal
      contraception.

      We will be administering three drugs in this study: Testim (testosterone (T) gel),
      dutasteride (which affects testosterone break down) and Depomedoxyprogesterone (DMPA, a
      progestin). We want to see their effects on levels of hormones in the blood and prostate. In
      addition, we will be examining the effects of these drugs on the expression of genes within
      the prostate. DMPA suppresses LH and FSH, which are hormones made by the pituitary gland,
      thus blocking the signal from the brain that causes the testes to make testosterone.
      Prolonged (&gt; 1 month) low levels of LH and FSH cause decreased sperm production in normal
      men. However, men may experience some side effects from the low levels of testosterone caused
      by DMPA; adding testosterone to DMPA eliminates these side effects while more effectively
      blocking LH and FSH release and sperm production. This combination of drugs is a promising
      male contraceptive regimen. However, the effect of these drugs on the prostate is not known.
      Some studies suggest that testosterone administration may promote prostate growth.
      Dutasteride blocks the conversion of testosterone to dihydrotestosterone and is used to treat
      men with enlarged prostates. Dutasteride shrinks the prostate. It is possible that combining
      testosterone and dutasteride may be an effective part of a male hormonal contraceptive
      regime. Therefore, further studies examining the effect of testosterone, DMPA and dutasteride
      on the prostate are needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific Antigen (PSA)</measure>
    <time_frame>10 weeks</time_frame>
    <description>PSA level week 10 end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone Concentration</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone (DHT) Concentration</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Androstenedione (AED)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone (DHEA)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel + Placebo pill + placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>Testosterone gel 10 g</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>dutasteride 0.5 mg orally</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Medroxyprogesterone (DMPA)</intervention_name>
    <description>300 mg DMPA injection on Day 0 IM (into the muscle)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Depo-Provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Testosterone gel</intervention_name>
    <description>Place gel applied daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo dutasteride</intervention_name>
    <description>placebo pill for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo DMPA</intervention_name>
    <description>placebo DMPA injection Once</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men in good health, and without a history of chronic androgen therapy or known history
             of gonadal or prostate abnormalities.

               -  PSA ≤ 2.

               -  Age 25-55 years

               -  Ability to understand the study,study procedures and provide consent

               -  Normal serum total T, LH, FSH, urine analyses, and sperm count &gt; or equal to
                  15million/ml

               -  International Prostate Symptom Score (IPSS) &lt; 10

               -  Normal seminal fluid analysis (&gt;20 million sperm/ml)

               -  Agree not to donate blood during the treatment and recovery periods

        Exclusion Criteria:

          -  A history or evidence of prostate or breast cancer

          -  History of invasive therapy for BPH

          -  History of acute urinary retention

          -  Current or past treatment with a 5α-reductase inhibitor

          -  History of anti/androgenic drugs or drugs that interfere with steroid metabolism
             within past 3 months

          -  Severe systemic illness (renal, liver, cardiac, lung disease, cancer, poorly
             controlled diabetes)

          -  Known untreated obstructive sleep apnea

          -  Hematocrit &gt; 52%

          -  Skin disease that might interfere with T gel absorption

          -  Hypersensitivity to any of the drugs used in the study

          -  History of a bleeding disorder or anticoagulation

          -  History of drug or alcohol abuse within 12 months

          -  History of infertility or desire for fertility within 12 months, or current pregnant
             partner

          -  A first-degree relative (i.e. father, brother) with a history of prostate cancer

          -  Abnormal digital rectal examination or prostate ultrasound
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie T Page, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr/is Dedicated to basic and clinical research focused primarily on the male reproductive system.</description>
  </link>
  <reference>
    <citation>Amory JK, Page ST, Bremner WJ. Drug insight: Recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab. 2006 Jan;2(1):32-41. Review.</citation>
    <PMID>16932251</PMID>
  </reference>
  <reference>
    <citation>Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D, Anderson RA, Bremner WJ, Pollanen P, Nieschlag E, Wu FC, Kersemaekers WM. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod. 2006 Jan;21(1):285-94. Epub 2005 Sep 19.</citation>
    <PMID>16172147</PMID>
  </reference>
  <reference>
    <citation>Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004 Apr;190(4 Suppl):S5-22. Review.</citation>
    <PMID>15105794</PMID>
  </reference>
  <reference>
    <citation>Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001 Dec;58(6 Suppl 1):5-16; discussion 16. Review.</citation>
    <PMID>11750242</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Wilson JD, George FW. The Physiology of Reproduction. Raven Press, 1994</citation>
  </reference>
  <reference>
    <citation>Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61. Review.</citation>
    <PMID>7979239</PMID>
  </reference>
  <reference>
    <citation>Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.</citation>
    <PMID>12824459</PMID>
  </reference>
  <reference>
    <citation>Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 1990 Dec;71(6):1552-5.</citation>
    <PMID>1699965</PMID>
  </reference>
  <reference>
    <citation>Geller J, Albert J. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res. 1987;15(3):151-3.</citation>
    <PMID>3629749</PMID>
  </reference>
  <reference>
    <citation>Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004 Jan 15;10(2):440-8.</citation>
    <PMID>14760063</PMID>
  </reference>
  <reference>
    <citation>Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab. 1989 Feb;68(2):461-8.</citation>
    <PMID>2465302</PMID>
  </reference>
  <reference>
    <citation>Habib FK, Ross M, Tate R, Chisholm GD. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clin Endocrinol (Oxf). 1997 Feb;46(2):137-44.</citation>
    <PMID>9135694</PMID>
  </reference>
  <reference>
    <citation>Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. Epub 2006 Aug 1.</citation>
    <PMID>16882745</PMID>
  </reference>
  <reference>
    <citation>Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006 Nov;91(11):4374-80. Epub 2006 Aug 29.</citation>
    <PMID>16940442</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>June 19, 2013</results_first_submitted>
  <results_first_submitted_qc>September 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Stephanie T. Page</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Male Contraception</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Testis</keyword>
  <keyword>Contraception</keyword>
  <keyword>Prostate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy male volunteers, 25-55 yr old, were recruited via advertisement: flyers on University campus and newspaper ads.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1) Placebo</title>
          <description>Placebo gel + Placebo pill + placebo DMPA</description>
        </group>
        <group group_id="P2">
          <title>2) Testosterone (T) Gel</title>
          <description>Testosterone 1% transdermal gel 10g (Testim)+ placebo pill, daily + placebo DMPA</description>
        </group>
        <group group_id="P3">
          <title>3) T Gel+Dutasteride</title>
          <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
        </group>
        <group group_id="P4">
          <title>4) T Gel+DMPA</title>
          <description>Testosterone 1% transdermal gel 10g, daily + placebo Dutasteride pill, daily + DMPA 300mg injection (IM)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>noncompliant with drug administration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1) Placebo</title>
          <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
        </group>
        <group group_id="B2">
          <title>2) Testosterone Gel</title>
          <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
        </group>
        <group group_id="B3">
          <title>3) T Gel +Dutasteride</title>
          <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
        </group>
        <group group_id="B4">
          <title>4) T Gel+ DMPA</title>
          <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="7.72"/>
                    <measurement group_id="B2" value="37" spread="6.19"/>
                    <measurement group_id="B3" value="37" spread="8.45"/>
                    <measurement group_id="B4" value="39" spread="10.11"/>
                    <measurement group_id="B5" value="39" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Male population, per protocol</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Luteinizing Hormone (LH)</title>
          <units>IU/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="3.5" upper_limit="5.6"/>
                    <measurement group_id="B2" value="3.9" lower_limit="2.7" upper_limit="5.5"/>
                    <measurement group_id="B3" value="5.3" lower_limit="4.2" upper_limit="6.6"/>
                    <measurement group_id="B4" value="3.2" lower_limit="2.7" upper_limit="4.0"/>
                    <measurement group_id="B5" value="4.1" lower_limit="3.3" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follical-stimulating hormone (FSH)</title>
          <units>IU/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" lower_limit="2.6" upper_limit="4.4"/>
                    <measurement group_id="B2" value="3.3" lower_limit="2.6" upper_limit="3.7"/>
                    <measurement group_id="B3" value="4.0" lower_limit="2.4" upper_limit="5.5"/>
                    <measurement group_id="B4" value="2.8" lower_limit="2.6" upper_limit="4.2"/>
                    <measurement group_id="B5" value="3.4" lower_limit="2.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SHBG</title>
          <units>nmol/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B2" value="36" lower_limit="13" upper_limit="50"/>
                    <measurement group_id="B3" value="38" lower_limit="26" upper_limit="52"/>
                    <measurement group_id="B4" value="33" lower_limit="17" upper_limit="38"/>
                    <measurement group_id="B5" value="35" lower_limit="20" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone (T) concentration</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" lower_limit="3.8" upper_limit="5.0"/>
                    <measurement group_id="B2" value="3.9" lower_limit="2.9" upper_limit="5.9"/>
                    <measurement group_id="B3" value="4.8" lower_limit="3.8" upper_limit="6.3"/>
                    <measurement group_id="B4" value="4.0" lower_limit="3.0" upper_limit="5.8"/>
                    <measurement group_id="B5" value="4.1" lower_limit="3.4" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dihydrotestosterone (DHT)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="B2" value="0.6" lower_limit="0.4" upper_limit="0.9"/>
                    <measurement group_id="B3" value="0.7" lower_limit="0.6" upper_limit="1.0"/>
                    <measurement group_id="B4" value="0.6" lower_limit="0.4" upper_limit="0.8"/>
                    <measurement group_id="B5" value="0.6" lower_limit="0.4" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate-Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" lower_limit="0.6" upper_limit="1.0"/>
                    <measurement group_id="B2" value="0.7" lower_limit="0.4" upper_limit="1.1"/>
                    <measurement group_id="B3" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="B4" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="B5" value="0.7" lower_limit="0.5" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate volume</title>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="B2" value="15" lower_limit="14" upper_limit="19"/>
                    <measurement group_id="B3" value="15" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="B4" value="19" lower_limit="14" upper_limit="21"/>
                    <measurement group_id="B5" value="18" lower_limit="14" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate-specific Antigen (PSA)</title>
        <description>PSA level week 10 end of treatment</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Placebo</title>
            <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
          </group>
          <group group_id="O2">
            <title>2) Testosterone Gel</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
          </group>
          <group group_id="O3">
            <title>3) T Gel +Dutasteride</title>
            <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
          </group>
          <group group_id="O4">
            <title>4) T Gel+ DMPA</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA)</title>
          <description>PSA level week 10 end of treatment</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.7" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.3" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Testosterone Concentration</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Placebo</title>
            <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
          </group>
          <group group_id="O2">
            <title>2) Testosterone Gel</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
          </group>
          <group group_id="O3">
            <title>3) T Gel +Dutasteride</title>
            <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
          </group>
          <group group_id="O4">
            <title>4) T Gel+ DMPA</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Concentration</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.9" upper_limit="5.6"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="7.0" lower_limit="4.4" upper_limit="12.4"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.3" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dihydrotestosterone (DHT) Concentration</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Placebo</title>
            <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
          </group>
          <group group_id="O2">
            <title>2) Testosterone Gel</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
          </group>
          <group group_id="O3">
            <title>3) T Gel +Dutasteride</title>
            <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
          </group>
          <group group_id="O4">
            <title>4) T Gel+ DMPA</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Dihydrotestosterone (DHT) Concentration</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.2" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.2" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androstenedione (AED)</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Placebo</title>
            <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
          </group>
          <group group_id="O2">
            <title>2) Testosterone Gel</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
          </group>
          <group group_id="O3">
            <title>3) T Gel +Dutasteride</title>
            <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
          </group>
          <group group_id="O4">
            <title>4) T Gel+ DMPA</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione (AED)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.8" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.8" upper_limit="1.3"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.3" upper_limit="3.7"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.6" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydroepiandrosterone (DHEA)</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Placebo</title>
            <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
          </group>
          <group group_id="O2">
            <title>2) Testosterone Gel</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
          </group>
          <group group_id="O3">
            <title>3) T Gel +Dutasteride</title>
            <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
          </group>
          <group group_id="O4">
            <title>4) T Gel+ DMPA</title>
            <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydroepiandrosterone (DHEA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.7" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.0" upper_limit="7.5"/>
                    <measurement group_id="O3" value="3.8" lower_limit="3.8" upper_limit="6.3"/>
                    <measurement group_id="O4" value="3.2" lower_limit="2.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1) Placebo</title>
          <description>Placebo Testosterone gel + Placebo Dutasteride pill + placebo DMPA</description>
        </group>
        <group group_id="E2">
          <title>2) Testosterone Gel</title>
          <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + placebo DMPA</description>
        </group>
        <group group_id="E3">
          <title>3) T Gel +Dutasteride</title>
          <description>Testosterone 1% transdermal gel 10g + dutasteride 0.5mg Orally + placebo DMPA</description>
        </group>
        <group group_id="E4">
          <title>4) T Gel+ DMPA</title>
          <description>Testosterone 1% transdermal gel 10g + placebo Dutasteride + DMPA 300mg injection (IM)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>abscess</sub_title>
                <description>leg abscess - unrelated trauma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephanie Page</name_or_title>
      <organization>University of Washington</organization>
      <phone>2066160483</phone>
      <email>page@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

